In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in health and wellness solutions, has uncovered issues with share issuance ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas ...

The distinct population of endothelial cells that line blood vessels in the insulin-producing "islets" of the human pancreas have been notoriously ...

Sharp Imaging and Information Company of America (SIICA), a division of Sharp Electronics Corporation (SEC), today announced ...

The president of the University of Minnesota said a slash in funding for medical research grants by the National Institutes ...

Vimentin is a type III intermediate filament (IF) protein normally expressed in cells that develop into connective tissue, blood vessels, and lymphatic tissue (mesenchymal cells). Despite being widely ...

Doug Kellogg, professor of molecular, cell, and developmental biology at UC Santa Cruz, has been awarded $2.95 million from ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...